Title:
AI for drug design - search for caix inhibitors
Agreement Value:
$160,500.00
Agreement Date:
Apr 16, 2020 - Mar 31, 2023
Description:
Designing a drug for a specific disease type is highly challenging due to tremendous molecular search space and limited understanding about the disease of interest. Successful discovery of a medicine for a target (gene/protein/pathway) usually last for many years and costs a private pharmaceutical organization billions of dollars, which in turn determines the unaffordable price of medicines in the Canadian and global markets. The emerging of massive biochemical and high-throughput genomic data acquisition techniques and the rise of advanced artificial intelligence paradigms provide an unprecedented opportunity for automatic design of new drugs with much faster pace and much lower cost, igniting hopes to discovery drugs for diseases where no medicines have been found yet. In this project, the aim is to develop a data- and AI-driven drug design platform/pipeline for precise and effective treatment of cancers and complex diseases. It is possible to take the advantages of NRC’s unique multidisciplinary expertise in AI, data science, and human health therapeutics, as well as recipient’s knowledge and facilities, to tackle challenges in every step of drug design. Project technologies and outcomes will be disruptive and beneficial to all Canadians. This project will focus on search for small molecules carbonic anhydrase IX (CAIX) novel inhibitors. The recipient will provide expertise in CAIX binding and enzymatic assays, wet lab validation and experimental analysis of designed drug candidates for inhibiting CAIX activity and impact to tumor growth in vitro and in vivo.
Organization:
National Research Council Canada
Expected Results:
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Location:
Vancouver, British Columbia, CA V5Z 1L3
Reference Number:
172-2021-2022-Q3-948772
Report Type:
Grants and Contributions
Recipient Business Number:
851840538
Recipient Type:
Not-for-profit organization or charity
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 160,500 dollars and the end date of this agreements has been modified by 365 days.
Amendment Date
Sep 15, 2021
Recipient's Legal Name:
BC Cancer, part of the Provincial Health Services Authority
Federal Riding Name:
Vancouver Granville
Federal Riding Number:
59036
Program:
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Purpose:
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.